MARKET

STOK

STOK

Stoke Therapeutics
NASDAQ
32.15
-0.45
-1.37%
Opening 10:50 08/28 EDT
OPEN
32.20
PREV CLOSE
32.59
HIGH
32.55
LOW
31.72
VOLUME
120.54K
TURNOVER
--
52 WEEK HIGH
40.22
52 WEEK LOW
18.00
MARKET CAP
2.07B
P/E (TTM)
-9.5701
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at STOK last week (0817-0821)?
Weekly Report · 4d ago
Stoke Therapeutics Price Target Announced at $40.00/Share by JP Morgan
Dow Jones · 6d ago
JP Morgan Reinstates Overweight on Stoke Therapeutics, Announces $40 Price Target
Benzinga · 6d ago
Stoke Therapeutics reinstated with an Overweight at JPMorgan
TipRanks · 08/21 10:30
Is Strong EMPEROR Trial Enrollment and Retention Altering The Investment Case For Stoke Therapeutics (STOK)?
Simply Wall St · 08/20 03:31
Is Stoke Therapeutics (STOK) A Bargain On Its EMPEROR Trial Enrollment Milestone?
Simply Wall St · 08/19 01:27
Weekly Report: what happened at STOK last week (0810-0814)?
Weekly Report · 08/17 10:15
Stoke Therapeutics (STOK) Gets a Buy from Canaccord Genuity
TipRanks · 08/13 12:45
More
About STOK
Stoke Therapeutics, Inc. is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with ribonucleic acid (RNA)-based medicines. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, zorevunersen (STK-001), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The Company is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.

Webull offers Stoke Therapeutics Inc stock information, including NASDAQ: STOK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, STOK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading STOK stock methods without spending real money on the virtual paper trading platform.